

1 SARS-CoV-2 Infections in mRNA Vaccinated Individuals are Biased for Viruses Encoding Spike E484K
2 and Associated with Reduced Infectious Virus Loads that Correlate with Respiratory Antiviral IgG levels.

3

4 Heba H. Mostafa^{1*}, Chun Huai Luo¹, C. Paul Morris^{1,2}, Maggie Li³, Nicholas J. Swanson³, Adannaya
5 Amadi¹, Nicholas Gallagher¹, Andrew Pekosz^{3,4*}

6

7 ¹Johns Hopkins School of Medicine, Department of Pathology, Division of Medical Microbiology

8 ²National Institute of Allergy and Infectious Disease, National Institutes of Health

9 ³W. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins

10 Bloomberg School of Public Health, Baltimore, Maryland, USA.

11 ⁴Department of Emergency Medicine, Johns Hopkins School of Medicine

12

13 * Corresponding authors

14 hmostaf2@jhmi.edu

15 600 N. Wolfe St, Meyer B-121F, Baltimore, MD 21287. (410) 955-5077

16 apekosz1@jhu.edu

17 615 North Wolfe Street, rm W2116, Baltimore, MD 21205-2103. (410) 502-9306

18

19 Abstract: 331 words

20 Text: 2635 words

21 Figures: 5

22 Tables: 1 and 5 supplemental

23

24

25 **Abstract**

26 **Introduction**

27 COVID-19 large scale immunization in the US has been associated with infrequent breakthrough
28 positive molecular testing. Whether a positive test is associated with a high viral RNA load, specific
29 viral variant, recovery of infectious virus, or symptomatic infection is largely not known.

30 **Methods**

31 In this study, we identified 133 SARS-CoV-2 positive patients who had received two doses of either
32 Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) vaccines, the 2nd of which was received
33 between January and April of 2021. The positive samples were collected between January and May of
34 2021 with a time that extended from 2 to 100 days after the second dose. Samples were sequenced to
35 characterize the whole genome and Spike protein changes and cycle thresholds that reflect viral loads
36 were determined using a single molecular assay. Local SARS-CoV-2 IgG antibodies were examined
37 using ELISA and specimens were grown on cell culture to assess the recovery of infectious virus as
38 compared to a control unvaccinated cohort from a matched time frame.

39 **Results**

40 Of 133 specimens, 24 failed sequencing and yielded a negative or very low viral load on the repeat PCR.
41 Of 109 specimens that were used for further genome analysis, 68 (62.4%) were from symptomatic
42 infections, 11 (10.1%) were admitted for COVID-19, and 2 (1.8%) required ICU admission with no
43 associated mortality. The predominant virus variant was the alpha (B.1.1.7), however a significant
44 association between lineage B.1.526 and amino acid change S: E484K with positives after vaccination
45 was noted when genomes were compared to a large control cohort from a matched time frame. A
46 significant reduction of the recovery of infectious virus on cell culture as well as delayed time to the first
47 appearance of cytopathic effect was accompanied by an increase in local IgG levels in respiratory
48 samples of vaccinated individuals but upper respiratory tract IgG levels were not different between
49 symptomatic or asymptomatic infections.

50 **Conclusions**

51 Vaccination reduces the recovery of infectious virus in breakthrough infections accompanied by an
52 increase in upper respiratory tract local immune responses.

53 **Funding**

54 National Institute of Health (The Johns Hopkins Center of Excellence in Influenza Research and
55 Surveillance, HHSN272201400007C), Johns Hopkins University, Maryland Department of
56 Health, Centers for Disease Control and Prevention.

57

58 **Introduction**

59 SARS-CoV-2 has caused a devastating pandemic. Millions of global deaths have been recorded with
60 thousands of new cases diagnosed daily, a trend that significantly changed with the large-scale
61 vaccination in certain countries including the US (<https://coronavirus.jhu.edu/map.html>). Even though
62 vaccines currently used have high efficacy (1, 2) and undoubtedly, have reduced COVID-19 mortality
63 and severe disease in countries that accelerated mass immunization (3), breakthrough infections have
64 been reported. As of June 1st 2021, the Centers for Disease Control and Prevention (CDC) reported that
65 more than 135 million have been fully vaccinated in the US but so far, the CDC was only notified of
66 3,016 cases of breakthrough infections that required hospitalization or were associated with mortality
67 (<https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html>). The frequency
68 of asymptomatic infections though might be underestimated and the relationship between the immune
69 status, viral loads, and recovery of infectious virus from vaccinated positives are largely not known.
70 With the appearance of SARS-CoV-2 variants that are more transmissible or capable of evading vaccine
71 induced immune responses, surveillance has become of utmost importance and genome characterization
72 of positives after vaccination is essential. Currently, data support that vaccines approved for use in the
73 US are effective against most of the currently circulating variants (4)(5). With the general increase in the
74 circulation of variants of concern, it is expected to see a high percentage of breakthrough infections
75 caused by these variants. In our laboratory, as a part of high throughput sequencing for surveillance,
76 positives after full vaccination are genotyped. In addition, viruses are characterized on cell culture to
77 determine the association of virus genotypes and RNA loads with the recovery of infectious virus.
78 In this manuscript, we provide a comprehensive analysis of 133 positives after vaccination diagnosed by
79 Johns Hopkins Clinical Microbiology laboratory. Samples were enrolled in our whole genome
80 sequencing for surveillance pipeline and were retested by the PerkinElmer PCR assay to obtain
81 comparable cycle threshold values (Cts). The recovery of infectious virus from positives after
82 vaccination was determined as well as local SARS-CoV-2 IgG levels in the respiratory samples using
83 ELISA and compared to a control unvaccinated cohort.

84 **Methods**

85 *Ethical considerations and Data availability*

86 The research Johns Hopkins Medical Institutions Institutional Review Board-X (JHM IRB-X) is
87 constituted to meet the requirements of the Privacy Rule at section 45 CFR 164.512(i)(1)(i)(B) and is
88 authorized and qualified to serve as the Privacy Board for human subjects research applications
89 conducted by Johns Hopkins University faculty members. JHM IRB-3 approved IRB00221396 entitled
90 “Genomic evolution of viral pathogens: impact on clinical severity and molecular diagnosis”. IRB
91 review included the granting of a waiver of consent based on the following criteria: 1) the research
92 involves no more than minimal risk to subjects; 2) the waiver will not adversely affect the rights and
93 welfare of the subjects; 3) the research could not be practicably carried out without the waiver; and 4)
94 the IRB will advise if it is appropriate for participants to be provided with additional pertinent
95 information after participation. This study was also approved for the inclusion of children as 'research
96 not involving greater than minimal risk'. The permission of parents/guardians is waived. Assent is
97 waived for all children. JHM IRB-X determined that there is no requirement for continuing review or
98 progress report for this application. Remnant nasopharyngeal or lateral mid-turbinate nasal (NMT)
99 clinical swab specimens from patients who tested positive for SARS-CoV-2 after the standard of care
100 testing were used.

101

102 *Nucleic acid extraction, PCR, and whole genome sequencing*

103 Automated nucleic acid extraction was performed using the chemagic 360 (PerkinElmer) following the
104 manufacturer’s protocol, with an RNA elution volume of 60µL. Real-time reverse transcriptase PCR
105 (rRT-PCR) was performed using the PerkinElmer SARS-CoV-2 Real-time RT-PCR Assay following
106 the package insert (<https://www.fda.gov/media/136410/download>). Libraries were prepared in 96 well
107 plates using the ARTIC protocol as previously described (6) with additional clean-up steps using Mag-
108 bind beads prior to combining samples into a single library. Sequencing was performed using the

109 Oxford Nanopore GridION and reads were basecalled with MinKNOW and demultiplexed with
110 guppybarcoder. Reads were size restricted, and alignment and variant calling were performed with the
111 artic-ncov2019 medaka protocol. Clades were determined using Nextclade beta v 0.12.0
112 (clades.nextstrain.org) (7), and lineages were determined with Pangolin COVID-19 lineage Assigner
113 (COG-UK (cog-uk.io)).

114

115 *ELISA*

116 The EUROIMMUN Anti-SARS-CoV-2 ELISA (IgG) was run using undiluted respiratory samples and
117 following the package insert (<https://www.fda.gov/media/137609/download>). This assay detects
118 antibodies to the S1 domain of the spike protein of SARS-CoV-2. The assay has a cut-off < 0.8 for
119 negative results and ≥ 0.8 to < 1.1 as borderline, which we used as a cut off for nasopharyngeal/ NMT
120 swab specimen types even though these sources were not tested by the manufacturer.

121

122 *Cell culture*

123 Vero-TMPRSS2 cells were cultured and infected with aliquots of swab specimens as previously
124 described for VeroE6 cells (8). The presence of SARS-CoV-2 was confirmed by reverse transcriptase
125 PCR (qPCR).

126

127 *Statistical analyses*

128 Statistics were performed using GraphPad Prism. For Lineage and Spike analyses Samples with $\geq 90\%$
129 genome coverage were selected from both vaccinated and control groups (N = 67 for the vaccinated
130 group, and 335 for the control group, Supplementary tables 1 and 3). Controls were selected from
131 samples previously submitted by our group to GISAID, using MatchIt in R (method= 'optimal', ratio=5)
132 based on collection date. Control and vaccinated samples were plotted over time to verify a good match.
133 Percentage of samples that matched to lineages were plotted. The full set of mutations present within the
134 spike protein of vaccinated patients were determined, and a heatmap of percentage of samples from

135 vaccinated and control groups was plotted. Chi-square analysis of lineages with at least 5 samples
136 showed a correlation between lineage and vaccine status ($p = 0.006$). Chi-square analysis was
137 performed for lineages P.1, B.1.1.7, B.1.351, B.1.526, and B.1.526.1.

138

139 **Results**

140 **SARS-CoV-2 genomes of positives after full vaccination**

141 As a part of whole genome sequencing of SARS-CoV-2 for surveillance, we identified 133 positives
142 after the completion of either Moderna or Pfizer vaccination regimes that were collected in the time
143 frame of January 2021- May 2021 (Table 1 summarizes the clinical and metadata of this cohort). Of the
144 133 samples, 24 had failed sequencing with 0% coverage which we believe was related to very low viral
145 loads or false positivity (Supplementary table 1). Twenty-one sequences had coverage less than 50% and
146 average depth of less than 50 and a lineage was not called. Of the genomes that had more than 50%
147 coverage and more than an average depth of 50 (a total of 88), the majority (61%) belonged to the
148 B.1.1.7 (alpha variant) lineage (20I/501Y.V1 clade) followed by the 20C lineages (iota variants) B.1.526
149 (9%) and B.1.526.1 (4.5%) (Figure 1A and B). A significant correlation between genome coverage and
150 days of sample collection in relation to the second dose of vaccination was noted when all samples with
151 coverage $> 1\%$ were included in this analysis (109 total, Supplementary table 1 and Figure 1C, Linear
152 regression, $p = 0.049$). To correlate genome coverage with the clinical assay's Ct values, samples were
153 rerun by one diagnostic assay (PerkinElmer) to obtain comparable Ct values. Of the 109 samples with
154 coverage $> 1\%$, 92 specimens had sufficient left-over volumes and were retrieved for rRT-PCR. A
155 significant correlation between Ct values and % coverage was noted with a complete or nearly complete
156 genome coverage associated with Ct values below 25 (Figure 1D, Linear regression, $p < 0.0001$).

157 When a large cohort of our characterized genomes were randomly selected as a control based on the
158 sample collection dates and only genomes with $\geq 90\%$ coverage were used for the analysis (vaccinated:
159 $N = 67$, and control: $N = 335$), an association was seen between B.1.526 and vaccination status (Chi-
160 square with Bonferroni correction $p = 0.022$, Figure 1E). Spike substitution analysis showed that the S:

161 E484K is associated with genomes of the vaccinated group ($p = 0.0032$, Figure 1F and Supplementary
162 tables 3, 4, and 5).

163 **Recovery of infectious virus from fully vaccinated individuals and the correlation with local**
164 **SARS-CoV-2 antibodies and viral loads**

165 To assess the recovery of infectious virus from positive samples of fully vaccinated individuals, first, a
166 cohort of control samples was selected. A total of 124 positive samples from unvaccinated individuals
167 collected in the time frame between the end of December 2020 to the first week of March 2021 were
168 used for comparison (Supplementary table 2). The cohort was selected to include the alpha variant
169 lineage as well as other predominant lineages before the month of March. To compare the recovery of
170 infectious virus between positives from fully vaccinated ($N = 114$ with sufficient volume) and control
171 ($N = 124$) groups, samples were cultured on Vero-TMPRSS2 cells and the time to cytopathic effect
172 (CPE) was compared between the two groups. As expected, samples that had failed sequencing and
173 were thought of as very low viral load or false positives did not yield infectious virus and were excluded
174 from further analysis (Supplementary table 1). Of the fully vaccinated group, 17 of 92 samples (18.5%)
175 showed CPE on cell culture compared to 80 out of 124 (64.5%) of the control group (Fisher Exact test, p
176 < 0.00001). Notably, the control group recovery on cell culture was faster than the vaccinated group
177 with 44 out of 80 samples (55%) positive 2 days after culture compared to no samples showing CPE for
178 the vaccinated group (Figure 2 A and B).

179 To study the local SARS-CoV-2 antibodies in the respiratory samples and their correlation to the
180 observed CPE phenotype, respiratory samples grown on cell culture were also tested by ELISA for
181 SARS-CoV-2 IgG. A significant increase in SARS-CoV-2 nasal and nasopharyngeal IgG levels were
182 noted in the respiratory samples from vaccinated individuals when compared to the control group
183 (Figure 2C, t test, $P < 0.0001$).

184 To better understand the contribution of Ct values and local antibodies on virus recovery on cell culture,
185 we focused our analysis on samples with Ct values below 25 which constituted 49 samples in the
186 vaccinated group versus 96 samples in the control group (Supplementary tables 1 and 2). Notably the

187 distribution of the Ct values between the two groups for samples with Ct values lower than 25 was not
188 different (Figure 3A). The majority of the control group samples were positive on cell culture (77,
189 80.2%), in contrast to 17 (34.7%) of the vaccinated group (Figure 3B). Consistent with data from the
190 whole cohort, higher nasal/ nasopharyngeal IgG levels (Figure 3C, $P < 0.0001$) was noted for the fully
191 vaccinated group.

192 **Characterization of local SARS-CoV-2 antibody responses.**

193 A correlation of SARS-CoV-2 local IgG with the days of sample collection after receiving the second
194 dose of the COVID-19 vaccine showed a trend of reduction with the progress of time (Figure 4A, linear
195 regression, $p < 0.0001$). No significant correlations between the IgG levels and Ct values were noticed
196 (Figure 4B). Negative recovery of infectious virus on cell culture correlated with high levels of IgG in
197 respiratory specimens, with no infectious virus isolated from samples with an IgG OD reading of >3.0
198 (Figure 4C, t test, $P = 0.004$). The presence of symptoms did not correlate with higher IgG levels when
199 we compared samples from symptomatic vaccinated to asymptomatic vaccinated individuals (Figure
200 5A). Notably, a significant increase in the mean Ct value for the asymptomatic group was noted (27.6
201 versus 23.2, t test, $P = 0.0048$, Figure 5B) as well as a reduction in the mean genome coverage (70.8%
202 versus 84.9%, t test, $P = 0.0284$, Figure 5C). Notably, infectious virus was recovered from only 2
203 samples from asymptomatic patients (6.5%) in contrast to 15 from symptomatic patients (24.6%)
204 (Supplementary table 1).

205

206 **Discussion**

207 In this study, we provide a comprehensive analysis on a cohort of 133 SARS-CoV-2 positive specimens
208 collected after the completion of COVID-19 vaccination. This cohort was enrolled in our whole genome
209 sequencing for SARS-CoV-2 surveillance. Genomic analysis revealed that only 67 had genomic
210 coverage of $\geq 90\%$ and when compared to a random cohort of our characterized genomes from a
211 matched time frame, there was a statistically significant increased representation of lineage B.1.526 as
212 well as the Spike amino acid change S:E484K. Strikingly, when samples with Ct values less than 25

213 were compared to a control cohort of similarly distributed Ct values, the recovery of infectious virus
214 from cases post-vaccination was significantly impaired, evident as both a delay in the first appearance of
215 cytopathic effect as well as a significant decrease in the total number of positive samples on cell culture.
216 This data indicates that infection in vaccinated individuals results in reduced infectious virus load
217 compared to unvaccinated individuals and that the Ct value from infected, vaccinated individuals is
218 associated with lower infectious virus loads compared to unvaccinated individuals. This may further
219 reduce the likelihood that infected, vaccinated individuals can transmit SARS-CoV-2 to others.
220 Interestingly, the lower infectious virus load in vaccinated individuals was associated with an increase in
221 local SARS-CoV-2 specific IgG levels. The reduction in infectious virus in samples with Ct values of
222 less than 25 could be explained if the nasal SARS-CoV-2 IgGs are neutralizing. The recovery of
223 infectious virus was higher in symptomatic when compared to asymptomatic vaccinated individuals, but
224 local SARS-CoV-2 IgG levels were comparable between symptomatic and asymptomatic cases,
225 indicating that local antiviral IgG levels do not drive higher asymptomatic infection rates.
226 Recent data from the CDC showed that the widely used mRNA vaccines in the US reduce the infection
227 risk by 91% and data from different groups confirm that breakthrough infections after full vaccination
228 are scarce (9-11). Data also show that vaccines reduce symptomatic and asymptomatic infections (12-
229 14). Our data is consistent with published data, and even though the total number of infections after
230 vaccination is not known, the occurrence of positives after full vaccination in our surveillance cohort has
231 been infrequent. Our data show that the 18% of 133 positive individuals who tested positives after the
232 second dose were likely false positives or had very low viral loads that rendered the repeat rRT-PCR
233 runs and sequencing negatives. Our data also show that 37.6 % of these breakthrough infections were
234 asymptomatic and in symptomatic patients, the majority were mild cases that did not require
235 hospitalization.
236 The correlation between positive PCR results and the recovery of infectious virus after COVID-19
237 vaccination was not previously reported, however in vivo animal studies showed that vaccines reduce
238 viral replication in the respiratory tracts of animals (15-17). Vaccines were also shown to reduce SARS-

239 CoV-2 transmission and a recent report showed a reduction in viral RNA loads after vaccination (18).
240 Our data show that, despite a similar distribution of Ct values in vaccinated and control unvaccinated
241 individuals, the recovery of infectious virus after vaccination is significantly attenuated. The recovery of
242 infectious virus though could still infrequently happen and hence might be associated with reduced
243 transmission. Additional studies are required to determine the kinetics of infectious virus shedding in
244 vaccinated individuals.

245 The emergence of SARS-CoV-2 variants of concern and interest were associated with changes in the
246 spike protein within regions that could affect the receptor binding domain or impact the neutralization of
247 the virus by natural or vaccine induced immune responses (19-22). Those variants were associated with
248 an increase in transmissibility and in particular the S: E484K substitution was associated with a
249 compromise in the neutralization by monoclonal antibodies rendering this change “of therapeutic
250 concern”. The S: E484K independently emerged in multiple lineages in distant geographical locations
251 including the B.1.351 and the P.1 and those lineages showed some reduction in neutralization by sera
252 collected from immunized individuals as well as decreased susceptibility to certain therapeutic
253 monoclonal antibodies. Additionally, the B.1.351 and P.1 were associated with reductions in the vaccine
254 efficacy data in locations of its predominance (23, 24). The S: E484K is also present in some strains of
255 lineage B.1.526, a lineage which was significantly associated with positives after vaccination in our
256 cohort, even though in a previous study, it was not reported to associate with positives after vaccination
257 (25). Our study shows that the S: E484K is significantly associated with breakthrough cases after
258 vaccination in a well-controlled analysis that used a large cohort of controls from a matched time frame
259 of sample collection. This data highlights the significance of continuous genomic surveillance coupled
260 with metadata and laboratory data collections for providing significant information with the potential to
261 impact decisions related to booster doses or modifying vaccine strains.

262 In conclusion, this is the first study that combines genomic analysis, cell culture, and mucosal serology
263 to correlate reduced recovery of infectious virus from positives after vaccination with increased local

264 IgG levels. This study is also the first to show the significant association of S: E484K with positives
265 after full vaccination using a well-controlled analysis and a relatively large sample size.

266

267 **Declaration of interests**

268 We declare no relevant competing interests

269

270 **Data sharing**

271 Whole genome data were made available publicly and raw genomic data requests could be directed to
272 HHM.

273

274 **Acknowledgement**

275 This study was only possible with the unique efforts of the Johns Hopkins Clinical Microbiology
276 Laboratory faculty and staff. We also thank the Johns Hopkins Immunology Laboratory and Kim
277 Jeemin for technical assistance. HHM is supported by the HIV Prevention Trials Network (HPTN)
278 sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), National Institute on
279 Drug Abuse, National Institute of Mental Health, and Office of AIDS Research, of the NIH, DHHS
280 (UM1 AI068613), the NIH RADx-Tech program (3U54HL143541-02S2), National Institute of
281 Health RADx-UP initiative (Grant R01 DA045556-04S1), National Institute of Allergy and Infectious
282 Diseases (Johns Hopkins Center of Excellence in Influenza Research and Surveillance
283 HHSN272201400007C), the U. S. Centers for Disease Control (75D30121C11061), Johns Hopkins
284 University President's Fund Research Response, the Johns Hopkins Department of Pathology, and the
285 Maryland Department of Health. This research was supported in part by the intramural research program
286 of the National Institutes of Health. The views expressed in this manuscript are those of the authors and
287 do not necessarily represent the views of the National Institute of Biomedical Imaging and
288 Bioengineering; the National Heart, Lung, and Blood Institute; the National Institutes of Health, the U.S.
289 Centers for Disease Control or the U.S. Department of Health and Human Services.

290 **References**

- 291 1. Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB,
292 Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T,
293 Brandon DM, Thomas SJ, Tureci O, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen
294 KU, Gruber WC, Group CCT. 2021. Safety, Immunogenicity, and Efficacy of the BNT162b2
295 Covid-19 Vaccine in Adolescents. *N Engl J Med* doi:10.1056/NEJMoa2107456.
- 296 2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA,
297 Roupheal N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C,
298 Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J,
299 Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W,
300 Zhou H, Han S, Ivarsson M, Miller J, Zaks T, Group CS. 2021. Efficacy and Safety of the
301 mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 384:403-416.
- 302 3. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B,
303 Balicer RD. 2021. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination
304 Setting. *N Engl J Med* 384:1412-1423.
- 305 4. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for C-V. 2021. Effectiveness
306 of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med*
307 doi:10.1056/NEJMc2104974.
- 308 5. Woldemeskel BA, Garliss CC, Blankson JN. 2021. SARS-CoV-2 mRNA vaccines induce broad
309 CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. *J Clin Invest*
310 131.
- 311 6. Thielen PM, Wohl S, Mehoke T, Ramakrishnan S, Kirsche M, Falade-Nwulia O, Trovao NS,
312 Ernlund A, Howser C, Sadowski N, Morris CP, Hopkins M, Schwartz M, Fan Y, Gniazdowski
313 V, Lessler J, Sauer L, Schatz MC, Evans JD, Ray SC, Timp W, Mostafa HH. 2021. Genomic
314 diversity of SARS-CoV-2 during early introduction into the Baltimore-Washington metropolitan
315 area. *JCI Insight* 6.

- 316 7. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T,
317 Neher RA. 2018. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34:4121-
318 4123.
- 319 8. Gniazdowski V, Morris CP, Wohl S, Mehoke T, Ramakrishnan S, Thielen P, Powell H, Smith
320 B, Armstrong DT, Herrera M, Reifsnnyder C, Sevdali M, Carroll KC, Pekosz A, Mostafa HH.
321 2020. Repeat COVID-19 Molecular Testing: Correlation of SARS-CoV-2 Culture with
322 Molecular Assays and Cycle Thresholds. *Clin Infect Dis* doi:10.1093/cid/ciaa1616.
- 323 9. Jacobson KB, Pinsky BA, Rath MEM, Wang H, Miller JA, Skhiri M, Shepard J, Mathew R, Lee
324 G, Bohman B, Parsonnet J, Holubar M. 2021. Post-vaccination SARS-CoV-2 infections and
325 incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California
326 academic medical center. medRxiv doi:10.1101/2021.04.14.21255431.
- 327 10. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus
328 G, Pan K, Southern J, Swerdlow DL, Jodar L, Levy Y, Alroy-Preis S. 2021. Impact and
329 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19
330 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an
331 observational study using national surveillance data. *Lancet* 397:1819-1829.
- 332 11. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, Ben-Ami R. 2021. Association
333 Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic
334 SARS-CoV-2 Infections Among Health Care Workers. *JAMA* doi:10.1001/jama.2021.7152.
- 335 12. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, Murad MH, Berbari EF,
336 Virk A. 2021. Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a
337 cohort of healthcare personnel. *Clin Infect Dis* doi:10.1093/cid/ciab361.
- 338 13. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-
339 Martinez AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski
340 E, Edwards LJ, Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic
341 L, Wesley MG, Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J,

- 342 Brown RT, Herring MK, Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR,
343 Arvay ML, Kutty P, Fry AM, Gaglani M. 2021. Interim Estimates of Vaccine Effectiveness of
344 BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection
345 Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -
346 Eight U.S. Locations, December 2020-March 2021. *MMWR Morb Mortal Wkly Rep* 70:495-
347 500.
- 348 14. Tang L, Hijano DR, Gaur AH, Geiger TL, Neufeld EJ, Hoffman JM, Hayden RT. 2021.
349 Asymptomatic and Symptomatic SARS-CoV-2 Infections After BNT162b2 Vaccination in a
350 Routinely Screened Workforce. *JAMA* doi:10.1001/jama.2021.6564.
- 351 15. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Flach B,
352 O'Connell S, Bock KW, Minai M, Nagata BM, Andersen H, Martinez DR, Noe AT, Douek N,
353 Donaldson MM, Nji NN, Alvarado GS, Edwards DK, Flebbe DR, Lamb E, Doria-Rose NA, Lin
354 BC, Louder MK, O'Dell S, Schmidt SD, Phung E, Chang LA, Yap C, Todd JM, Pessaint L, Van
355 Ry A, Browne S, Greenhouse J, Putman-Taylor T, Strasbaugh A, Campbell TA, Cook A,
356 Dodson A, Steingrebe K, Shi W, Zhang Y, Abiona OM, Wang L, Pegu A, Yang ES, Leung K,
357 Zhou T, Teng IT, Widge A, et al. 2020. Evaluation of the mRNA-1273 Vaccine against SARS-
358 CoV-2 in Nonhuman Primates. *N Engl J Med* 383:1544-1555.
- 359 16. Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan
360 K, Tostanoski LH, He X, Martinez DR, Rutten L, Bos R, van Manen D, Vellinga J, Custers J,
361 Langedijk JP, Kwaks T, Bakkers MJG, Zuijdgeest D, Rosendahl Huber SK, Atyeo C, Fischinger
362 S, Burke JS, Feldman J, Hauser BM, Caradonna TM, Bondzie EA, Dagotto G, Gebre MS,
363 Hoffman E, Jacob-Dolan C, Kirilova M, Li Z, Lin Z, Mahrokhian SH, Maxfield LF, Nampanya
364 F, Nityanandam R, Nkolola JP, Patel S, Ventura JD, Verrington K, Wan H, Pessaint L, Van Ry
365 A, Blade K, Strasbaugh A, Cabus M, et al. 2020. Single-shot Ad26 vaccine protects against
366 SARS-CoV-2 in rhesus macaques. *Nature* 586:583-588.

- 367 17. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC,
368 Hein S, Guler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG,
369 Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek
370 B, Sanger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P,
371 Schlereth J, Schille S, Kroner C, de la Caridad Guimil Garcia R, Hiller T, Fischer L, Sellers RS,
372 Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K,
373 Griffor MC, Han S, Su AAH, Lees JA, et al. 2021. BNT162b vaccines protect rhesus macaques
374 from SARS-CoV-2. *Nature* 592:283-289.
- 375 18. Levine-Tiefenbrun M, Yelin I, Katz R, Herzog E, Golan Z, Schreiber L, Wolf T, Nadler V, Ben-
376 Tov A, Kuint J, Gazit S, Patalon T, Chodick G, Kishony R. 2021. Initial report of decreased
377 SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. *Nat Med* 27:790-792.
- 378 19. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB,
379 Tong S, Silk BJ, Armstrong GL, Biggerstaff M, Dugan VG. 2021. Emergence of SARS-CoV-2
380 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal*
381 *Wkly Rep* 70:95-99.
- 382 20. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, Pearson CAB, Russell
383 TW, Tully DC, Washburne AD, Wenseleers T, Gimma A, Waites W, Wong KLM, van
384 Zandvoort K, Silverman JD, Group CC-W, Consortium C-GU, Diaz-Ordaz K, Keogh R, Eggo
385 RM, Funk S, Jit M, Atkins KE, Edmunds WJ. 2021. Estimated transmissibility and impact of
386 SARS-CoV-2 lineage B.1.1.7 in England. *Science* 372.
- 387 21. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD,
388 Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng
389 Z, Huang Y, Ho DD. 2021. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
390 *Nature* 593:130-135.

- 391 22. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, Liu L, Kwong PD, Huang Y, Shapiro
392 L, Ho DD. 2021. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization.
393 Cell Host Microbe 29:747-751 e4.
- 394 23. Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers
395 C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch
396 DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T,
397 Hardt K, Ruiz-Guinazu J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M,
398 Group ES. 2021. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.
399 N Engl J Med 384:2187-2201.
- 400 24. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL,
401 Barnabas SL, Borat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL,
402 Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S,
403 Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I,
404 Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus
405 R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian
406 AM, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against
407 SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa,
408 and the UK. Lancet 397:99-111.
- 409 25. Thompson CN, Hughes S, Ngai S, Baumgartner J, Wang JC, McGibbon E, Devinney K, Luoma
410 E, Bertolino D, Hwang C, Kepler K, Del Castillo C, Hopkins M, Lee H, DeVito AK, Rakeman
411 JL, PhD, Fine AD. 2021. Rapid Emergence and Epidemiologic Characteristics of the SARS-
412 CoV-2 B.1.526 Variant - New York City, New York, January 1-April 5, 2021. MMWR Morb
413 Mortal Wkly Rep 70:712-716.




Figure 1. SARS-CoV-2 genomes of positives after full vaccination. A) Lineages and B) Clades of genomes with more than 50% coverage and average depth of 50 (n=88). C) A correlation of SARS-CoV-2 genome coverage with the days of sample collection after the second dose of vaccination. D) A correlation between SARS-CoV-2 genome coverage and cycle thresholds of the N gene using the PerkinElmer SARS-CoV-2 assay. E) A comparison between lineages from

fully vaccinated (n = 67) and control (n = 335) genomes with coverage \geq 90%. F) Spike amino acid changes in vaccinated and control groups. * $p < 0.05$, *** $p < 0.005$




Figure 2. Recovery of infectious SARS-CoV-2 on Vero-TMPRSS2 cells for A) fully vaccinated and B) control groups. C) SARS-CoV-2 IgG in upper respiratory swab samples from fully vaccinated and control groups. Dashed line demarcates the limit of borderline and negative ELISA results as specified per assay's package insert (1.1). * $p < 0.05$, *** $p < 0.0001$




Figure 3. Recovery of infectious SARS-CoV-2 on Vero-TMPRSS2 cells for samples with Ct values less than 25 (N gene). A) comparison of Ct values distribution between control and fully vaccinated groups. B) Days to CPE in control and fully vaccinated groups. C) IgG in vaccinated and control groups respiratory samples. Dashed line demarcates the limit of borderline and negative ELISA results as specified per assay's package insert (1.1). * $p < 0.05$, *** $p < 0.0001$




Figure 4. **Local SARS-CoV-2 antibodies in upper respiratory samples of vaccinated individuals.** A) IgG levels by ELISA in the upper respiratory samples collected from patients positive after full vaccination (N=114) and association with the days after receiving the second dose of the COVID-19 vaccine. B) SARS-CoV-2 IgG correlation to cycle thresholds of the N gene using the PerkinElmer SARS-CoV-2 assay. C) SARS-CoV-2 IgG correlation to days to the

first appearance of cytopathic effect (CPE) on Vero-TMPRSS2 cells. Dashed line demarcates the limit of borderline and negative ELISA results as specified per assay's package insert.




Figure 5. Local antibodies, viral loads, and recovery of whole genomes in symptomatic versus asymptomatic vaccinated individuals. A) IgG levels by ELISA in the upper respiratory samples. B) Comparison of Ct values distribution between symptomatic and asymptomatic groups. C) % genome coverage in symptomatic and asymptomatic groups. Dashed line demarcates the limit of borderline and negative ELISA results as specified per assay's package insert. * $p < 0.05$, ** $p < 0.005$

	Positives after full vaccination	Positives after full vaccination (viral load below the limit of detection or false positives)
Total number of patients	109	24
Median age in years (range)	51 (23 - >90)	52 (23 - 79)
No. (%) of		
Male	40 (36.7)	6 (25)
Female	69 (63.3)	18 (75)
Symptomatic	68 (62.4)	8 (28.6)
Asymptomatic	41 (37.6)	16 (66.6)
Severity index (%):		
Outpatient	95 (87.2)	24 (100)
Hospitalized for COVID-19	11 (10.1)	0
ICU admission	2 (1.8)	0
Past Medical History Information (%)		
Obesity (BMI > 30)	18 (16.5)	3 (12.5)
Hypertension	13 (11.9)	6 (25)
Cardiovascular disease	13 (11.9)	1 (4.2)
Diabetes	17 (15.6)	4 (16.7)
Asthma/ chronic lung disease	16 (14.7)	5 (20.8)
Kidney disease	11 (10.1)	2 (8.3)
History of cancer/ autoimmune disease/ HIV/ potentially immunocompromised	13 (11.9)	1 (4.2)
Median days after COVID-19 vaccine (range)	52 (2 - 99)	19.5 (3 - 100)

Table 1. Clinical and metadata of breakthrough infection cases.